Abstract CT016: Clinical activity of single-agent ZN-c3, an oral WEE1 inhibitor, in a phase 1 dose-escalation trial in patients with advanced solid tumorsAnthony W. Tolcher, D. Voliotis, Hirva Mamdani et al.|Cancer Research|2021Cited by 24
Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C. Gangadhar, April K.S. Salama, F. Stephen Hodi et al.|Journal of Immunotherapy|2017Cited by 18
526P Pharmacodynamic evidence for WEE1 target engagement in surrogate and tumor tissues from a phase I study of the WEE1 inhibitor ZN-c3Pavani Chalasani, Fernando Doñate, Anthony W. Tolcher et al.|Annals of Oncology|2021Cited by 1
Safety and Efficacy of Pembrolizumab in US Patients Enrolled in KEYNOTE-030, an Expanded Access ProgramRomina P. Oxborough, April K.S. Salama, Tara C. Gangadhar et al.|Unknown|2015Cited by 0